Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Northeast Colorado Conference Discusses HIV/AIDS Needs Assessment Findings
Rural Solutions, an organization in northeast Colorado, held the "Community HIV/AIDS Education and Action Conference" as part of its ongoing effort to address issues related to HIV, the Sterling Journal-Advocate reports. At the conference, the organization presented the results of a recent needs assessment of HIV/AIDS services in the northeastern part of the state - conducted in partnership with the Center for Research Strategies and funded through the Colorado Department of Public Health and Environment - which found that HIV prevention services in the area are limited; barriers exist for HIV testing including confidentiality and costs; and mental health and substance use services for at-risk people also are limited, according to the Journal-Advocate (Jones, Sterling Journal-Advocate, 6/17).

Regional Center For Biodefense And Emerging Infectious Diseases Research Funded By NIH
A consortium of research centers in the Tri-state Region, including Albert Einstein College of Medicine of Yeshiva University, has received a $46 million grant to conduct research on emerging infectious diseases.
News of the day
Study Rewrites Textbook On Key Genetic Phenomenon
Because females carry two copies of the X chromosome to males" one X and one Y, they harbor a potentially toxic double dose of the over 1000 genes that reside on the X chromosome.
Mental Health

Inoperable Colon Cancer Responds To New Treatment

With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation"s new protocol. The Tennessee patient"s early results mirror their successes in battling colon cancer and other very aggressive malignancies. The most recent colon cancer patient is a man in his late fifties who had an extensive cancer of the lower colon diagnosed in early 2008. Initially his doctors recommended surgical resection in an operation that would have removed all the organs of his lower abdomen and pelvis; however, it was determined that he would be unlikely to survive the procedure. Chemotherapy was tried, but was ineffective. He visited NeoPlas Innovation"s Nashville clinic in the spring of 2009 and began the new outpatient treatment. Two months later, CT scans have shown that the cancer has regressed dramatically. The patient"s symptoms are resolving in step with the response, with improvements in appetite and digestion and the regaining of lost weight. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are results from one patient, so no conclusions can be drawn. But this is consistent with the favorable responses we"re seeing in the great majority of our patients, including those with colon cancer." The protocol is offered for qualifying patients with colon cancer, renal (kidney) cancer, pancreatic cancer, melanoma, mesothelioma and certain sarcomas. It can be considered for other patients on a case-by-case basis. The new treatment is an off-label combination of two existing medicines: lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to moving from the lab to success in humans has been taking a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, the results have been surprising." NeoPlas Innovation patients often have seen the arrest of their cancers" growth and spread in as few as eight weeks of treatment. In many cases, such as this one, patients have experienced active regression of tumors. The medicines used have the advantage of being safe and well tolerated. Fatigue is the most notable side effect of NeoPlas Innovation"s cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment. NeoPlas Innovation"s web site, http://www.neoplas.org, provides complete information and an interactive screening tool for patients who are considering this treatment. The clinic can be reached at (615) 371-8100. NeoPlas Innovation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009